Although we did not have these samples available, tissues and PBMC from patients with hematologic malignancies who received PD‐1 ICB therapy should be analyzed to study the dynamics of CXCR5+PD‐1+ CD8 T cells to definitely prove association with response to therapy. Here, CD8A is linked to hematologic disorder.